Wednesday 22 December 2010

Savella: Cypress Bio Bought by Ramius

 
Zacks Equity Research
December 17, 2010
Product Portfolio at Cypress Bio
With this acquisition, Royalty Pharma will gain access to Cypress Bio’s Savella royalty stream. Savella, which is indicated for the treatment of fibromyalgia, is the only marketed product at Cypress Bio.
Savella has been developed under an agreement with Forest Labs and Cypress Bio receives a 15% royalty on product sales. The company was previously co-promoting Savella with Forest Labs. However, the co-promotion agreement was terminated in August 2010.
http://www.zacks.com/stock/news/44844/Cypress+Bio+Bought+by+Ramius

No comments:

Post a Comment